Biotech PNV hit fresh 52-week highs in July following the release of its unaudited FY24 trading results. FY24 sales of $92.0 million were up 54.5% yoy, driven by growth across the whole business. This is a solid result, but the share price, as is commonly the case with the ASX200 above 8000, isn’t compelling above $2.60.
- We will re-evaluate PNV after its full report tomorrow, the 23rd of August.
MM is neutral towards PNV ~$2.60
Add To Hit List
